Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from InSilico Medicine Cayman TopCo ( (HK:3696) ) is now available.
InSilico Medicine Cayman TopCo announced that the over-allotment option related to its recent global share offering has been fully exercised, resulting in the issuance of 14,203,500 additional shares at HK$24.05 each, equivalent to 15% of the shares initially offered. The new shares, which have received listing approval and are expected to begin trading on January 21, 2026, will be used to return stock borrowed from major shareholder Aleksandrs Zavoronkov to cover over-allocations in the international tranche, increasing the company’s total issued share capital to 571,622,000 shares and modestly diluting existing holdings while expanding the free float and reinforcing investor demand for the stock.
More about InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biotechnology and life sciences sector, focusing on drug discovery and development supported by advanced technologies and AI-driven research. Its shares trade on the Main Board of the Hong Kong Stock Exchange under stock code 3696, giving it access to international capital markets for its growth plans.
Average Trading Volume: 7,753,312
Current Market Cap: HK$32.3B
See more insights into 3696 stock on TipRanks’ Stock Analysis page.